Abstract 278P
Background
The advent of trastuzumab deruxtecan has led to the creation of a new treatment criterion for low HER2 expression (HER2-low : HER2 IHC score of 1+ or 2+/ISH not amplified). Utilizing 40 years of detailed clinical data from our hospital, the study aimed to investigate clinicopathological factors and long-term prognosis in HER2-low and HER2-zero breast cancer.
Methods
A total of 4,810 early-stage breast cancer cases were operated on and followed up from 1981 to 2022 at our hospital. We analyzed HER2 expression status in tumor tissues, clinicopathological factors, and prognosis in 3,788 cases excluding stage 0 cases.
Results
HER2-low cases accounted for 48% (1,819/3,788) of all cases analyzed, while HER2-zero cases comprised 34% (1,280/3,788). Among HER2-low cases, 89% were hormone receptor (HR) positive, with 11% classified as triple-negative (TN) breast cancer. In contrast, 83% of HER2-zero cases were HR positive, while 17% exhibited TN. Notably, HER2-zero cases showed a higher proportion of TN compared to HER2-low cases.
Prognostic analysis showed that the HER2-low group exhibited significantly superior outcomes in both disease-free survival (DFS) and overall survival (OS) compared to the HER2-zero group (p=0.005, p
Conclusions
In early-stage breast cancer, HER2-low patients had a better prognosis than HER2-zero patients, suggesting that HER2 expression status may result in different outcomes due to different hormone receptor expression rates and sensitivity to drug therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
T. Toyama: Non-Financial Interests, Personal and Institutional, Invited Speaker: Eli Lilly, Pfizer, Daiichi Sankyo, Chugai, Kyowa Kirin, Eisai; Non-Financial Interests, Personal, Invited Speaker: Taiho, AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
354P - Synergistic preclinical efficacy through combination of the CDK4 and CDK2 selective inhibitors, PF-07220060 and PF-07104091, respectively, in HR+ HER2- breast cancer
Presenter: Lars Anders
Session: Poster session 14
355P - EVERolimus effectiveness after proGREssion on CDK4/6 inhibitors for ENdocrine receptor-positive/HER2-negative, advanced breast cancer: EVERGREEN quasi-experimental study
Presenter: Soraia Lobo-Martins
Session: Poster session 14
356P - Real-world effectiveness in subgroups of palbociclib + endocrine therapy in HR+/HER2- ABC patients: Interim results of the PERFORM study
Presenter: Georg Pfeiler
Session: Poster session 14
358P - Everolimus or ribociclib in patients with HER2-negative, hormone-receptor positive metastatic breast cancer and circulating tumor cells: Results from DETECT IVa
Presenter: Tanja Fehm
Session: Poster session 14
359P - Overall survival of palbociclib (PAL) + endocrine therapy (ET) in Japanese patients with hormone receptor-positive (HR+)/ human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in the 1st line (1L) or 2nd line (2L) setting: A multicenter observational study
Presenter: Takahiro Nakayama
Session: Poster session 14
360P - Identification of circulating immune factors as predictive biomarkers of CDK4/6i treatment efficacy in advanced breast cancer
Presenter: Sara Cabrero-de las Heras
Session: Poster session 14
361P - PALVEN: A phase Ib study of palbociclib, letrozole and venetoclax in ER and BCL2-positive metastatic breast cancer
Presenter: Christine Muttiah
Session: Poster session 14
362P - Dose reductions due to treatment-related side effects and survival outcomes in breast cancer patients treated with CDK4/6 Inhibitors
Presenter: Pinar Kubilay Tolunay
Session: Poster session 14
363P - Palbociclib exposure in relation to response and toxicity in patients with advanced breast cancer
Presenter: Sanne Buijs
Session: Poster session 14